Press Release

• 05.06.08: Regulus Therapeutics Exclusively Licenses Intellectual Property from Stanford University Relating to microRNA Antagonists to Treat Inflammatory Diseases
• 04.17.08: GlaxoSmithKline and Regulus Therapeutics Form Strategic Alliance To Develop microRNA Targeted Therapeutics to Treat Inflammatory Diseases
• 02.11.08: Regulus Therapeutics Appoints Peter S. Linsley, Ph.D. as Chief Scientific Officer
• 12.12.07: Regulus Therapeutics and Collaborators Discover Role of Viral microRNAs in Cancer and Identify First-Ever Example of a Viral microRNA Oncogene
• 12.03.07: Regulus Therapeutics Appoints Kleanthis G. Xanthopoulos, Ph.D. as President and Chief Executive Officer
• 11.19.07: Regulus Therapeutics Announces Allowance of Key Patent on microRNA Therapeutics for the Treatment of Hepatitis C Virus Infection
• 10.25.07: Regulus Therapeutics and Collaborators Announce Publication of New Research on the Role of microRNAs in Regulating Pathways of Viral Infection
• 09.07.07: Isis and Alnylam Launch Regulus Therapeutics, a Joint Venture to Discover, Develop, and Commercialize microRNA Therapeutics
• 03.22.07: Alnylam and Stanford University Scientists Discover New Role for microRNAs (miRNAs) in T Cell Biology and Immunity
• 03.01.07: Alnylam and Isis Announce Allowance of First U.S. Patent Covering Human microRNAs
• 10.31.05: New RNAi Approach for In Vivo Therapeutic Silencing of MicroRNAs is Demonstrated by Alnylam and Rockefeller University Scientists
• 09.13.05: 09.13.05: Alnylam and Isis License Intellectual Property for microRNA Gene Involved in Hepatitis C Virus Infection
• 10.19.04: Alnylam and Isis Receive Exclusive License to Key microRNA Patents for Therapeutic Applications